Veronique Michaud, BPharm, MSc, PhD, is the President and Co-Founder of GalenusRx. Dr. Michaud earned her BPharm from Laval University, Quebec, Canada. She obtained her PhD and MSc degrees in pharmaceutical sciences from the Université de Montréal, Montreal, Canada. She then completed a postdoctoral fellowship at McGill University, Lady Davis Institute (Montreal, Canada) where she studied the pharmacogenomics (PGx) of HIV drugs. She completed a second fellowship at Indiana University, Department of Clinical Pharmacology (Indianapolis, IN) examining the role of PGx in the context of drug-drug interactions.
Previously, Dr. Michaud was the Chief Operating Officer of the Tabula Rasa HealthCare’s (TRHC) Precision Pharmacotherapy and Research Institute in Lake Nona, FL. She had been an adjunct professor, Faculty of pharmacy, Université de Montréal, and associate researcher at the CRCHUM (Centre de Recherche de l’Université de Montréal). She directed a pharmacokinetic and bioanalytic core facility at the CRCHUM, Montréal, Canada.
Dr. Michaud’s research interests investigate the contribution of CYP450 drug-metabolizing enzymes in drug disposition with a special attention to the role of disease, and PGx, while attempting to better understand and predict variation in drug responses. During her academic career, her work has led to a better cartography of CYP450 enzymes and drug transporters along the human intestine. Her research revealed the impact of type 2 diabetes as a factor leading to phenoconversion on specific isoforms and validation of endogenous biomarkers for the CYP450 phenotype.
Dr. Michaud always looks at better ways to transfer knowledge from basic research to clinical application using new technologies. Her innovative research includes working jointly with Dr. Jacques Turgeon in the development of InterMedRx®, a clinical-decision support system implemented in more than 200 community pharmacies, including Familiprix® and Walmart®, in three provinces and 10+ hospitals in Canada.
Throughout her career, she has highlighted her involvement with the development and implementation of differentiated clinical-decision support systems and medication safety assessment tools to help clinicians manage patients with polypharmacy. She has earned more than $22 million in research awards, published more than 88 peer-reviewed journal articles and more than 119 scientific abstracts, and mentored graduate students and PharmD residents. Her work has been cited more than 1,850 times since 2016.
